These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25656486)

  • 1. Pertussis outbreak in university students and evaluation of acellular pertussis vaccine effectiveness in Japan.
    Hara M; Fukuoka M; Tashiro K; Ozaki I; Ohfuji S; Okada K; Nakano T; Fukushima W; Hirota Y
    BMC Infect Dis; 2015 Feb; 15():45. PubMed ID: 25656486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine.
    Terranella A; Rea V; Griffith M; Manning S; Sears S; Farmer A; Martin S; Patel M
    Vaccine; 2016 May; 34(22):2496-500. PubMed ID: 27038131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Waning Tdap Effectiveness in Adolescents.
    Klein NP; Bartlett J; Fireman B; Baxter R
    Pediatrics; 2016 Mar; 137(3):e20153326. PubMed ID: 26908667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine.
    Klein NP; Bartlett J; Fireman B; Aukes L; Buck PO; Krishnarajah G; Baxter R
    Vaccine; 2017 Jun; 35(26):3395-3400. PubMed ID: 28506516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.
    Bechini A; Tiscione E; Boccalini S; Levi M; Bonanni P
    Vaccine; 2012 Jul; 30(35):5179-90. PubMed ID: 22709953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.
    Misegades LK; Winter K; Harriman K; Talarico J; Messonnier NE; Clark TA; Martin SW
    JAMA; 2012 Nov; 308(20):2126-32. PubMed ID: 23188029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.
    Koepke R; Eickhoff JC; Ayele RA; Petit AB; Schauer SL; Hopfensperger DJ; Conway JH; Davis JP
    J Infect Dis; 2014 Sep; 210(6):942-53. PubMed ID: 24903664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak.
    Bronson-Lowe D; Anderson SM
    Arch Pediatr Adolesc Med; 2009 May; 163(5):417-21. PubMed ID: 19414686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis.
    Wei SC; Tatti K; Cushing K; Rosen J; Brown K; Cassiday P; Clark T; Olans R; Pawloski L; Martin M; Tondella ML; Martin SW
    Clin Infect Dis; 2010 Aug; 51(3):315-21. PubMed ID: 20578875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of pertussis immune responses to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for outbreak control.
    Kirkland KB; Talbot EA; Decker MD; Edwards KM
    Clin Infect Dis; 2009 Aug; 49(4):584-7. PubMed ID: 19589084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children.
    Domenech de Cellès M; Rohani P; King AA
    JAMA Pediatr; 2019 Jun; 173(6):588-594. PubMed ID: 31009031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.
    Pool V; Tomovici A; Johnson DR; Greenberg DP; Decker MD
    Vaccine; 2018 Apr; 36(17):2282-2287. PubMed ID: 29573876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.
    van der Lee S; Sanders EAM; Berbers GAM; Buisman AM
    Vaccine; 2018 Jan; 36(2):220-226. PubMed ID: 29199041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
    Gidengil CA; Sandora TJ; Lee GM
    Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.